Gufic Biosciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: GUFICBIO BSE: 509079

₹432.00

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #63 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Gufic Biosciences Limited (this stock)	4,332	58.9	9.7%	23.0%	0.02%	53	8	51

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹4,657 Cr

EV / EBITDA

27.9x

EV / Sales

4.78x

Market cap / Sales

4.45x

Earnings yield

1.70%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 261 Cr, up 14.7% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	261	30	22	₹2.2400
March 31, 2026	252	28	21	₹2.0500
Dec. 31, 2025	231	21	16	₹1.5500
Sept. 30, 2025	230	21	15	₹1.4900
June 30, 2025	227	16	12	₹1.2000
March 31, 2025	205	11	8	₹0.8000
Dec. 31, 2024	208	26	19	₹1.9300
Sept. 30, 2024	204	29	22	₹2.1700
June 30, 2024	203	28	21	₹2.0800
March 31, 2024	195	27	20	₹2.0000
Dec. 31, 2023	202	30	22	₹2.2300
Sept. 30, 2023	215	31	23	₹2.3900
June 30, 2023	195	28	21	₹2.1300

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	261	251	232	233	228	205	210	204	204	196	202	215	196
Operating revenue	261	252	231	230	227	205	208	204	203	195	202	215	195
Other income	0	-1	1	2	1	0	2	0	1	1	0	0	1
Operating expenses	214	206	195	195	195	178	174	166	167	161	165	176	160
Operating profit	47	46	36	36	32	27	34	39	36	34	36	39	35
Operating profit margin	17.9%	18.2%	15.7%	15.5%	14.3%	13.0%	16.3%	18.9%	17.6%	17.6%	18.1%	18.3%	18.2%
Depreciation	8	8	8	8	8	8	5	4	4	4	4	4	4
Interest	9	9	8	10	9	8	5	5	5	4	3	4	4
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	30	28	21	21	16	11	26	29	28	27	30	31	28
Tax	8	7	5	6	4	3	7	7	7	7	7	8	7
Net profit	—	21	16	15	12	8	19	22	21	20	22	23	21
EPS	2.24	2.05	1.55	1.49	1.20	0.80	1.93	2.17	2.08	2.00	2.23	2.39	2.13
Net profit (TTM)	—	63	51	54	61	70	82	85	86	86	84	82	79
EPS (TTM)	7.33	6.29	5.04	5.42	6.10	6.98	8.18	8.48	8.70	8.75	8.62	8.49	8.19

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	940	85	63
March 31, 2025	820	94	70
March 31, 2024	807	116	86
March 31, 2023	691	107	80

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	10.8%	15.7%	943^†	823^†	809^†	693^†	782^†	455^†	365^†	355^†	307^†	250^†
Operating revenue	10.8%	15.8%	940	820	807	691	779^†	451^†	358^†	350^†	304^†	249^†
Other income	—	—	3^†	4^†	3^†	3^†	3^†	4^†	7^†	4^†	3^†	1^†
Operating expenses	—	—	790^†	685^†	661^†	559^†	633^†	378^†	313^†	304^†	—	218^†
Operating profit	4.6%	15.5%	150^†	135^†	146^†	131^†	146^†	73^†	45^†	46^†	—	31^†
Operating profit margin	—	—	16.0%^†	16.5%^†	18.0%^†	19.0%^†	18.7%^†	16.2%^†	12.5%^†	13.1%^†	—	12.6%^†
Depreciation	—	—	31^†	21^†	17^†	20^†	17^†	12^†	8^†	5^†	—	4^†
Interest	—	—	37^†	23^†	15^†	8^†	5^†	13^†	13^†	10^†	9^†	6^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	2^†	0^†
Profit before tax	-7.1%	10.4%	85	94	116	107	127^†	52^†	30^†	36^†	30^†	18^†
Tax	—	—	22^†	24^†	30^†	27^†	31^†	13^†	7^†	14^†	11^†	7^†
Net profit	-7.5%	10.3%	63	70	86	80	96^†	39^†	23^†	22^†	18^†	11^†
EPS	-8.6%	6.3%	6.29^†	6.98^†	8.75^†	8.23^†	9.89^†	4.64^†	2.94^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	16.0%^†	16.5%^†	18.0%^†	19.0%^†	18.7%^†	16.2%^†	12.5%^†	13.1%^†	—	12.6%^†
EBIT margin	13.0%^†	14.3%^†	16.2%^†	16.6%^†	16.9%^†	14.5%^†	12.0%^†	13.1%^†	12.6%^†	9.7%^†
PBT margin	9.1%	11.5%	14.3%	15.5%	16.3%^†	11.6%^†	8.5%^†	10.2%^†	9.7%^†	7.2%^†
Net margin	6.7%	8.5%	10.7%	11.5%	12.3%^†	8.6%^†	6.4%^†	6.3%^†	5.9%^†	4.6%^†
Interest coverage	3.33x^†	5.09x^†	8.53x^†	15.05x^†	27.17x^†	4.96x^†	3.38x^†	4.50x^†	4.33x^†	3.88x^†
Dividend payout	1.6%^†	1.4%^†	1.1%^†	1.2%^†	1.0%^†	1.1%^†	1.7%^†	—	—	—
Earnings retention	98.4%^†	98.6%^†	98.9%^†	98.8%^†	99.0%^†	98.9%^†	98.3%^†	—	—	—
Current ratio	1.55x	1.61x	—	—	—	—	—	—	—	—
Quick ratio	0.92x	1.05x	—	—	—	—	—	—	—	—
Debt to equity	0.58x	0.52x	—	—	—	—	—	—	—	—
Return on equity	9.5%	11.6%	—	—	—	—	—	—	—	—
Return on assets	4.7%	6.0%	—	—	—	—	—	—	—	—
Return on capital employed	14.8%^†	15.0%^†	—	—	—	—	—	—	—	—
Asset turnover	0.70x	0.70x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	44	-31	32	31	13
March 31, 2025	123	-72	-37	76	47
March 31, 2024	-7	-102	82	113	-120
March 31, 2023	-27	-191	234	188	-214
March 31, 2022	104	-96	-3	89	16

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,342	664	654	280	105	800	518	60	485	324
March 31, 2025	1,170	601	591	180	130	624	388	15	500	217
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.